Myelodysplastic syndromes: biology and treatment

被引：39

作者：

Jadersten, M. ^{[1
]}

Hellstrom-Lindberg, E.

机构：

[1] Karolinska Univ Hosp, Dept Med, Karolinska Inst, Div Hematol, Stockholm, Sweden

来源：

JOURNAL OF INTERNAL MEDICINE | 2009年 / 265卷 / 03期

基金：

英国医学研究理事会;

关键词：

del(5q); EPO; G-CSF; prognosis; RPS14; SPARC; ACUTE MYELOID-LEUKEMIA; COLONY-STIMULATING FACTOR; QUALITY-OF-LIFE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; COMMONLY DELETED REGION; CHRONIC MYELOMONOCYTIC LEUKEMIA; PROGNOSTIC SCORING SYSTEM; RIBOSOMAL-PROTEIN S19; RED-CELL APLASIA; TERM-FOLLOW-UP;

D O I：

10.1111/j.1365-2796.2008.02052.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Optimal management of patients with myelodysplastic syndromes (MDS) requires an insight into the biology of the disease and the mechanisms of action of the available therapies. This review focuses on low-risk MDS, for which chronic anaemia and eventual progression to acute myeloid leukaemia are the main concerns. We cover the updated World Health Organization classification, the latest prognostic scoring system, and describe novel findings in the pathogenesis of 5q- syndrome. We perform in depth analyses of two of the most widely used treatments, erythropoietin and lenalidomide, discussing mechanisms of action, reasons for treatment failure and influence on survival.

引用

页码：307 / 328

页数：22

共 203 条

[1] Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients [J].

Aggerholm, A ;

Holm, MS ;

Guldberg, P ;

Olesen, LH ;

Hokland, P .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 76 (01) :23-32

[2] Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells [J].

Aivado, M ;

Rong, A ;

Stadler, M ;

Germing, U ;

Giagounidis, A ;

Strupp, C ;

Novotny, J ;

Josten, KM ;

Kobbe, G ;

Hildebrandt, B ;

Gattermann, N ;

Aul, C ;

Haas, R ;

Ganser, A .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2002, 68 (04) :210-216

[3]

Alessandrino EP, 2002, HAEMATOLOGICA, V87, P1286

[4] NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features [J].

Andersen, M. T. ;

Andersen, M. K. ;

Christiansen, D. H. ;

Pedersen-Bjergaard, J. .

LEUKEMIA, 2008, 22 (05) :951-955

[5] Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders [J].

Angelucci, Emanuele ;

Barosi, Giovanni ;

Camaschella, Clara ;

Cappellini, Maria Domenica ;

Cazzola, Mario ;

Galanello, Renzo ;

Marchetti, Monia ;

Piga, Antonio ;

Tura, Sante .

HAEMATOLOGICA, 2008, 93 (05) :741-752

[6]

[Anonymous], 2008, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

[7]

[Anonymous], NCCN Clinical Practice Guidelines in Oncology - Breast Cancer

[8] EPIDEMIOLOGIC AND ETIOLOGIC ASPECTS OF MYELODYSPLASTIC SYNDROMES [J].

AUL, C ;

GATTERMANN, N ;

SCHNEIDER, W .

LEUKEMIA & LYMPHOMA, 1995, 16 (3-4) :247-262

[9] A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia [J].

Bacher, Ulrike ;

Haferlach, Torsten ;

Kern, Wolfgang ;

Haferlach, Claudia ;

Schnittger, Susanne .

HAEMATOLOGICA, 2007, 92 (06) :744-752

[10] Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study [J].

Balleari, E ;

Rossi, E ;

Clavio, M ;

Congiu, A ;

Gobbi, M ;

Grosso, M ;

Secondo, V ;

Spriano, M ;

Timitilli, S ;

Ghio, R .

ANNALS OF HEMATOLOGY, 2006, 85 (03) :174-180

← 1 2 3 4 5 6 7 8 9 10 →